scholarly journals Human Coronavirus HKU1 Infection of Primary Human Type II Alveolar Epithelial Cells: Cytopathic Effects and Innate Immune Response

PLoS ONE ◽  
2013 ◽  
Vol 8 (7) ◽  
pp. e70129 ◽  
Author(s):  
Samuel R. Dominguez ◽  
Emily A. Travanty ◽  
Zhaohui Qian ◽  
Robert J. Mason
2006 ◽  
Vol 291 (6) ◽  
pp. L1246-L1255 ◽  
Author(s):  
Carlos E. O. Baleeiro ◽  
Paul J. Christensen ◽  
Susan B. Morris ◽  
Michael P. Mendez ◽  
Steven E. Wilcoxen ◽  
...  

We have previously demonstrated that mice exposed to sublethal hyperoxia (an atmosphere of >95% oxygen for 4 days, followed by return to room air) have significantly impaired pulmonary innate immune response. Alveolar macrophages (AM) from hyperoxia-exposed mice exhibit significantly diminished antimicrobial activity and markedly reduced production of inflammatory cytokines in response to stimulation with LPS compared with AM from control mice in normoxia. As a consequence of these defects, mice exposed to sublethal hyperoxia are more susceptible to lethal pneumonia with Klebsiella pneumoniae than control mice. Granulocyte/macrophage colony-stimulating factor (GM-CSF) is a growth factor produced by normal pulmonary alveolar epithelial cells that is critically involved in maintenance of normal AM function. We now report that sublethal hyperoxia in vivo leads to greatly reduced alveolar epithelial cell GM-CSF expression. Systemic treatment of mice with recombinant murine GM-CSF during hyperoxia exposure preserved AM function, as indicated by cell surface Toll-like receptor 4 expression and by inflammatory cytokine secretion following stimulation with LPS ex vivo. Treatment of hyperoxic mice with GM-CSF significantly reduced lung bacterial burden following intratracheal inoculation with K. pneumoniae, returning lung bacterial colony-forming units to the level of normoxic controls. These data point to a critical role for continuous GM-CSF activity in the lung in maintenance of normal AM function and demonstrate that lung injury due to hyperoxic stress results in significant impairment in pulmonary innate immunity through suppression of alveolar epithelial cell GM-CSF expression.


2006 ◽  
Vol 36 (4) ◽  
pp. 906-918 ◽  
Author(s):  
Xuesong Qian ◽  
Kazunaga Agematsu ◽  
Gordon J. Freeman ◽  
Yoh-ichi Tagawa ◽  
Kazuo Sugane ◽  
...  

2013 ◽  
Vol 4 (2) ◽  
pp. 133 ◽  
Author(s):  
Xiao-xiao Meng ◽  
Rui-lan Wang ◽  
Shan Gao ◽  
Hui Xie ◽  
Jiu-ting Tan ◽  
...  

2011 ◽  
Vol 12 (1) ◽  
Author(s):  
Véronique Corbière ◽  
Violette Dirix ◽  
Sarah Norrenberg ◽  
Mattéo Cappello ◽  
Myriam Remmelink ◽  
...  

Praxis medica ◽  
2021 ◽  
Vol 50 (1-2) ◽  
pp. 35-43
Author(s):  
Snežana Leštarević ◽  
Slađana Savić ◽  
Leonida Vitković ◽  
Predrag Mandić ◽  
Milica Mijović ◽  
...  

Coronavirus Disease (COVID-19) is caused by the RNA virus SARS-CoV-2. The primary receptor for the virus is most likely Angiotensin-converting enzyme 2 (ACE2), and the virus enters the body by infecting epithelial cells of the respiratory tract. Through the activation of Toll Like Receptors (TLRs), epithelial cells begin to synthesize various biologically active molecules. The pathophysiology of the COVID 19 is primarily attributed to the hyperactivation of host's immune system due to direct damage to the cells, with consequent release of proinflammatory substances, but also due to the activation of the innate immune response through the activation of alveolar macrophages and dendrite cells (DC). A strong proinflammatory reaction causes damage to alveolar epithelial cells and vascular endothelium. Respiratory epithelial cells, alveolar macrophages and DC are likely to be the most important cells involved in the innate immune response to the virus, since prolonged and excessive SARS-CoV-2-induced activation of these cells leads to the secretion of cytokines and chemokines that massively attract leukocytes and monocytes to the lungs and cause lung damage.


2008 ◽  
Vol 294 (1) ◽  
pp. C47-C55 ◽  
Author(s):  
Lingyun Jia ◽  
Mingjiang Xu ◽  
Wei Zhen ◽  
Xun Shen ◽  
Yi Zhu ◽  
...  

Short-term hypoxic pretreatment is an effective approach to protect the lung from subsequent prolonged hypoxic injury under conditions such as lung transplantation, shock, and trauma. However, the signaling pathways are not well understood. By use of high-throughput, two-dimensional electrophoresis combined with mass spectrometry, we found that short-term hypoxic treatment upregulated calreticulin (CRT), an endoplasmic-reticulum stress protein, in A549 human type II alveolar epithelial cells. Genetic manipulation of CRT expression in A549 cells through small interferring RNA inhibition or overexpression demonstrated a positive correlation between CRT expression level and cell viability in subsequent prolonged hypoxia, which indicates that CRT is a key mediator of short-term hypoxia-induced cell protection. Importantly, CRT overexpression prevented reactive oxygen species (ROS) accumulation during prolonged hypoxia by inducing the expression of thioredoxin (TRX), an antioxidant, in A549 cells. Furthermore, CRT promoted the nuclear translocation of nuclear factor-E2-related factor 2, the transcription factor of TRX. Finally, overexpressing an inactive TRX mutant reversed the effects of CRT on ROS accumulation and cell protection. Our results demonstrate that CRT stimulates the anti-oxidant pathway and contributes to short-term hypoxia-induced protection in A549 type II alveolar epithelial cells, which may have potential therapeutic ramifications for hypoxic pulmonary diseases.


Sign in / Sign up

Export Citation Format

Share Document